Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

SGLT2 inhibitors to prevent diabetic kidney disease.

Fioretto P, Vettor R, Pontremoli R.

Lancet Diabetes Endocrinol. 2020 Jan;8(1):4-5. doi: 10.1016/S2213-8587(19)30387-0. No abstract available. Erratum in: Lancet Diabetes Endocrinol. 2020 Feb;8(2):e1.

PMID:
31862151
2.

Erratum. Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. Diabetes Care 2019;42:514-519.

Ceriello A, Rossi MC, De Cosmo S, Lucisano G, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, Russo G, Nicolucci A; AMD-Annals Study Group.

Diabetes Care. 2020 Feb;43(2):497. doi: 10.2337/dc20-er02. Epub 2019 Dec 11. No abstract available.

3.

Sudden death with massive hemoptysis from aortobronchial fistula.

Maffeis V, Simmini S, Rossato M, Fioretto P, Fallo F, Basso C, Rizzo S.

Cardiovasc Pathol. 2020 Jan - Feb;44:107158. doi: 10.1016/j.carpath.2019.107158. Epub 2019 Oct 24.

PMID:
31760244
4.

Characterization of subcutaneous and omental adipose tissue in patients with obesity and with different degrees of glucose impairment.

Belligoli A, Compagnin C, Sanna M, Favaretto F, Fabris R, Busetto L, Foletto M, Dal Prà C, Serra R, Prevedello L, Da Re C, Bardini R, Mescoli C, Rugge M, Fioretto P, Conci S, Bettini S, Milan G, Vettor R.

Sci Rep. 2019 Aug 5;9(1):11333. doi: 10.1038/s41598-019-47719-y.

5.

Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes.

Viazzi F, Bonino B, Mirijello A, Fioretto P, Giorda C, Ceriello A, Guida P, Russo GT, De Cosmo S, Pontremoli R; AMD-Annals Study Group.

J Hypertens. 2019 Apr;37(4):805-813. doi: 10.1097/HJH.0000000000001950.

PMID:
30817462
6.

Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study.

Ceriello A, Rossi MC, De Cosmo S, Lucisano G, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, Russo G, Nicolucci A; AMD-Annals Study Group.

Diabetes Care. 2019 Apr;42(4):514-519. doi: 10.2337/dc18-1471. Epub 2019 Feb 14. Erratum in: Diabetes Care. 2020 Feb;43(2):497.

PMID:
30765432
7.

Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes.

Viazzi F, Bonino B, Mirijello A, Fioretto P, Giorda C, Ceriello A, Guida P, Russo GT, De Cosmo S, Pontremoli R; AMD-Annals Study Group.

J Hypertens. 2019 Jan 7. doi: 10.1097/HJH.0000000000001950. [Epub ahead of print]

PMID:
30624364
8.

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes.

Mirijello A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Russo GT, Guida P, Pontremoli R, De Cosmo S; AMD ANNALS Study Group.

BMC Nephrol. 2018 Dec 4;19(1):347. doi: 10.1186/s12882-018-1136-6.

9.

Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals.

Viazzi F, Russo GT, Ceriello A, Fioretto P, Giorda C, De Cosmo S, Pontremoli R.

J Nephrol. 2019 Aug;32(4):517-525. doi: 10.1007/s40620-018-00561-3. Epub 2018 Nov 27. Review.

PMID:
30478509
10.

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Cosentino F, Ceriello A, Baeres FMM, Fioretto P, Garber A, Stough WG, George JT, Grant PJ, Khunti K, Langkilde AM, Plutzky J, Rydén L, Scheen A, Standl E, Tuomilehto J, Zannad F.

Eur Heart J. 2019 Sep 7;40(34):2907-2919. doi: 10.1093/eurheartj/ehy677. No abstract available.

PMID:
30445605
11.

Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions.

Gentile S, Strollo F, Viazzi F, Russo G, Piscitelli P, Ceriello A, Giorda C, Guida P, Fioretto P, Pontremoli R, De Cosmo S, The Amd-Annals Study Group.

J Diabetes Res. 2018 Sep 19;2018:7153087. doi: 10.1155/2018/7153087. eCollection 2018.

12.

Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative.

Lamacchia O, Viazzi F, Fioretto P, Mirijello A, Giorda C, Ceriello A, Russo G, Guida P, Pontremoli R, De Cosmo S.

Diabetol Metab Syndr. 2018 Jul 31;10:60. doi: 10.1186/s13098-018-0361-2. eCollection 2018.

13.

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.

Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators.

Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Erratum in: Diabetes Obes Metab. 2019 Jan;21(1):203.

14.

Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes.

Viazzi F, Greco E, Ceriello A, Fioretto P, Giorda C, Guida P, Russo G, De Cosmo S, Pontremoli R; AMD-Annals Study Group.

Kidney Blood Press Res. 2018;43(2):422-438. doi: 10.1159/000488255. Epub 2018 Mar 16.

15.

Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension: a real-life observational study.

Viazzi F, Ceriello A, Fioretto P, Giorda C, Guida P, Russo G, Greco E, De Cosmo S, Pontremoli R; AMD-Annals Study Group.

J Hypertens. 2018 Aug;36(8):1719-1728. doi: 10.1097/HJH.0000000000001749.

PMID:
29677050
16.

Publisher Correction: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.

Piscitelli P, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S.

Sci Rep. 2018 Apr 12;8(1):5999. doi: 10.1038/s41598-018-23163-2.

17.

Modifications of Resting Energy Expenditure After Sleeve Gastrectomy.

Bettini S, Bordigato E, Fabris R, Serra R, Dal Pra' C, Belligoli A, Sanna M, Compagnin C, Foletto M, Prevedello L, Fioretto P, Vettor R, Busetto L.

Obes Surg. 2018 Aug;28(8):2481-2486. doi: 10.1007/s11695-018-3190-3.

PMID:
29532316
18.

Diabetic kidney disease in the elderly: prevalence and clinical correlates.

Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A, Guida P, Giorda C, Cucinotta D, Pontremoli R, Fioretto P; AMD-Annals Study Group.

BMC Geriatr. 2018 Feb 2;18(1):38. doi: 10.1186/s12877-018-0732-4.

19.

Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function.

Gentile S, Piscitelli P, Viazzi F, Russo G, Ceriello A, Giorda C, Guida P, Fioretto P, Pontremoli R, Strollo F, De Cosmo S; AMD-Annals Study Group.

Oncotarget. 2017 Jun 28;8(37):62039-62048. doi: 10.18632/oncotarget.18816. eCollection 2017 Sep 22.

20.

Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus.

Viazzi F, Piscitelli P, Ceriello A, Fioretto P, Giorda C, Guida P, Russo G, De Cosmo S, Pontremoli R; AMD‐Annals Study Group.

J Am Heart Assoc. 2017 Sep 22;6(9). pii: e006745. doi: 10.1161/JAHA.117.006745.

21.

Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.

Piscitelli P, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S.

Sci Rep. 2017 Jun 12;7(1):3313. doi: 10.1038/s41598-017-03551-w. Erratum in: Sci Rep. 2018 Apr 12;8(1):5999.

22.

Glucose targets for preventing diabetic kidney disease and its progression.

Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2017 Jun 8;6:CD010137. doi: 10.1002/14651858.CD010137.pub2. Review.

23.

Incidence and Predictors of Hypoglycemia 1 Year After Laparoscopic Sleeve Gastrectomy.

Belligoli A, Sanna M, Serra R, Fabris R, Pra' CD, Conci S, Fioretto P, Prevedello L, Foletto M, Vettor R, Busetto L.

Obes Surg. 2017 Dec;27(12):3179-3186. doi: 10.1007/s11695-017-2742-2.

PMID:
28547566
24.

Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes.

Ceriello A, De Cosmo S, Rossi MC, Lucisano G, Genovese S, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, Russo G, Nicolucci A; AMD-Annals Study Group.

Diabetes Obes Metab. 2017 Nov;19(11):1570-1578. doi: 10.1111/dom.12976. Epub 2017 Jul 10.

PMID:
28432733
25.

A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.

Avogaro A, Giaccari A, Fioretto P, Genovese S, Purrello F, Giorgino F, Del Prato S.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):763-772. doi: 10.1080/17512433.2017.1322507. Epub 2017 May 2. Review.

PMID:
28431476
26.

Metabolic syndrome, serum uric acid and renal risk in patients with T2D.

Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Fioretto P, De Cosmo S, Pontremoli R; AMD-Annals Study Group.

PLoS One. 2017 Apr 19;12(4):e0176058. doi: 10.1371/journal.pone.0176058. eCollection 2017.

27.

Mechanisms linking empagliflozin to cardiovascular and renal protection.

Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E.

Int J Cardiol. 2017 Aug 15;241:450-456. doi: 10.1016/j.ijcard.2017.03.089. Epub 2017 Mar 23. Review.

PMID:
28395981
28.

Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.

Fioretto P, Avogaro A.

Expert Opin Pharmacother. 2017 Apr;18(5):517-527. doi: 10.1080/14656566.2017.1300253. Epub 2017 Mar 20. Review.

PMID:
28277831
29.

The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.

Vettor R, Inzucchi SE, Fioretto P.

Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11. No abstract available.

PMID:
28074254
30.

Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative.

Pacilli A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S; AMD-Annals Study Group.

Diabetes Metab Res Rev. 2017 May;33(4). doi: 10.1002/dmrr.2873. Epub 2017 Jan 10.

PMID:
27935651
31.

Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes.

Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovese S, Russo GT, Fioretto P, Guida P, De Cosmo S, Pontremoli R; AMD-Annals Study Group.

J Diabetes Complications. 2017 Feb;31(2):419-426. doi: 10.1016/j.jdiacomp.2016.10.030. Epub 2016 Oct 29.

PMID:
27884661
32.

Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, Wanner C, Kasiske BL, Wheeler DC, Groop PH; Conference Participants.

Kidney Int. 2016 Dec;90(6):1175-1183. doi: 10.1016/j.kint.2016.09.010.

33.

Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative.

Russo GT, De Cosmo S, Viazzi F, Pacilli A, Ceriello A, Genovese S, Guida P, Giorda C, Cucinotta D, Pontremoli R, Fioretto P; AMD-Annals Study Group.

Diabetes Care. 2016 Dec;39(12):2278-2287. Epub 2016 Oct 4.

PMID:
27703024
34.

Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes.

De Cosmo S, Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Fioretto P, Pontremoli R; AMD-Annals Study Group.

J Hypertens. 2016 Oct;34(10):2090-8. doi: 10.1097/HJH.0000000000001045.

PMID:
27457667
35.

SGLT2 Inhibitors and the Diabetic Kidney.

Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R.

Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.

PMID:
27440829
36.

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.

Fioretto P, Mansfield TA, Ptaszynska A, Yavin Y, Johnsson E, Parikh S.

Drugs Aging. 2016 Jul;33(7):511-22. doi: 10.1007/s40266-016-0382-1.

37.

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.

Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjöström CD.

Diabetologia. 2016 Sep;59(9):2036-9. doi: 10.1007/s00125-016-4017-1. Epub 2016 Jun 15. No abstract available.

38.

Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies.

Gilbert RE, Weir MR, Fioretto P, Law G, Desai M, Kline I, Shaw W, Meininger G.

Can J Diabetes. 2016 Jun;40(3):247-57. doi: 10.1016/j.jcjd.2015.11.005. Epub 2016 Mar 24.

39.

The effect of dapagliflozin on renal function in patients with type 2 diabetes.

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L.

J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19.

PMID:
26894924
40.

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.

Fioretto P, Giaccari A, Sesti G.

Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x. Review.

41.

The authors reply.

Kohan DE, Fioretto P, Tang W, List JF.

Kidney Int. 2014 Dec;86(6):1272. doi: 10.1038/ki.2014.291. No abstract available.

42.

Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patients.

Mauer M, Caramori ML, Fioretto P, Najafian B.

Nephrol Dial Transplant. 2015 Jun;30(6):918-23. doi: 10.1093/ndt/gfu279. Epub 2014 Sep 1. Review.

43.

The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: a neutral viewpoint.

Frontoni S, Solini A, Fioretto P, Natali A, Zuccalà A, Cosentino F, Penno G; Italian Society of Diabetology (SID)-Study Group on Diabetes, Hypertension and the Kidney.

Nutr Metab Cardiovasc Dis. 2014 Jun;24(6):577-84. doi: 10.1016/j.numecd.2014.01.004. Epub 2014 Jan 22.

PMID:
24582686
44.

Is diabetic nephropathy reversible?

Fioretto P, Barzon I, Mauer M.

Diabetes Res Clin Pract. 2014 Jun;104(3):323-8. doi: 10.1016/j.diabres.2014.01.017. Epub 2014 Jan 20. Review.

PMID:
24513120
45.

Residual macrovascular risk in 2013: what have we learned?

Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i).

Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26. Review.

46.

Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.

Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, Bishop L, Bonora E, Bunnag P, Chuang LM, Deerochanawong C, Goldenberg R, Harshfield B, Hernández C, Herzlinger-Botein S, Itoh H, Jia W, Jiang YD, Kadowaki T, Laranjo N, Leiter L, Miwa T, Odawara M, Ohashi K, Ohno A, Pan C, Pan J, Pedro-Botet J, Reiner Z, Rotella CM, Simo R, Tanaka M, Tedeschi-Reiner E, Twum-Barima D, Zoppini G, Carey VJ.

Circulation. 2014 Mar 4;129(9):999-1008. doi: 10.1161/CIRCULATIONAHA.113.002529. Epub 2013 Dec 18.

PMID:
24352521
47.
48.

Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function.

Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, Panagiotopoulos S, McNeil K, Baker ST, Fioretto P, Macisaac RJ.

Diabetes Care. 2013 Nov;36(11):3620-6. doi: 10.2337/dc12-2572. Epub 2013 Jul 8.

49.

Pancreas transplantation and reversal of diabetic nephropathy lesions.

Mauer M, Fioretto P.

Med Clin North Am. 2013 Jan;97(1):109-14. doi: 10.1016/j.mcna.2012.10.009. Epub 2012 Dec 7.

50.

Reversal of diabetic nephropathy: lessons from pancreas transplantation.

Fioretto P, Mauer M.

J Nephrol. 2012 Jan-Feb;25(1):13-8. doi: 10.5301/jn.5000061. Review.

PMID:
22241641

Supplemental Content

Loading ...
Support Center